In a short period of time, TransCelerate has achieved unprecedented progress, delivering tangible impact to benefit the broader biopharmaceutical industry. All this would not have been achievable without the active engagement and sponsorship from some of the most senior leaders in the industry.
In just a few years, our leaders have made significant strides toward our goal of making clinical development more efficient. TransCelerate leadership has an unwavering dedication to assessing, refining and creating processes to make the drug development environment efficient, safe and innovative.
Corporate Secretary, TransCelerate; SVP, Digital Sciences, Allergan
Treasurer, TransCelerate; SVP, Head of Global Clinical Trial Operations, Merck
Pharmacovigilance Steering Committee Chair, TransCelerate; Chief Safety Officer, Janssen
Oversight Committee Chair, TransCelerate; Vice President, Clinical Development Quality & Risk Management, GSK
Vice President, Global Engagement & Communications
Director, Finance & Administration
Director, Value & Implementation Portfolio
Executive Director, Portfolio Management Lead
Board of Directors
CEO, TransCelerate BioPharma Inc.
Chair of the Board, SVP, Global Head of Pharma Regulatory and Policy, Roche
Vice Chair of the Board, EVP, Chief Development Officer, Pfizer Inc.
SVP, Global Clinical Development, Merck Research Laboratories
SVP, Head of Development, GlaxoSmith Kline
Senior Vice President, Global Development, Novo Nordisk A/S
SVP, Global Development, Amgen
Vice President, Clinical Development Organization, Eli Lilly and Company
EVP and Chief R&D Officer, Allergan
Head of Global Clinical Operations, EMD Serono
Head of Global Clinical Operations (GCO), Bristol-Myers Squibb
President, Global Research & Development, Sanofi
Director, EVP, Shionogi & Co., Ltd.
Chief Medical Officer, Boehringer Ingelheim
Vice Chair of the Executive Committee and Chief Scientific Officer
Head, Global Development Operations, Novartis
Chief Medical Officer, AstraZeneca
Chief Medical Officer and President, Development, Astellas Pharma